Literature DB >> 19480563

PRAS40: target or modulator of mTORC1 signalling and insulin action?

Emmani B M Nascimento1, D Margriet Ouwens.   

Abstract

Alterations in signalling via protein kinase B (PKB/Akt) and the mammalian target of rapamycin (mTOR) frequently occur in type 2 diabetes and various human malignancies. Proline-rich Akt substrate of 40-kDa (PRAS40) has a regulatory function at the intersection of these pathways. The interaction of PRAS40 with the mTOR complex 1 (mTORC1) inhibits the activity of mTORC1. Phosphorylation of PRAS40 by PKB/Akt and mTORC1 disrupts the binding between mTORC1 and PRAS40, and relieves the inhibitory constraint of PRAS40 on mTORC1 activity. This review summarizes the signalling pathways regulating PRAS40 phosphorylation, as well as the dual function of PRAS40 as substrate and inhibitor of mTORC1 in the physiological situation, and under pathological conditions, such as insulin resistance and cancer.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19480563     DOI: 10.1080/13813450902988580

Source DB:  PubMed          Journal:  Arch Physiol Biochem        ISSN: 1381-3455            Impact factor:   4.076


  11 in total

1.  A herpesvirus kinase that masquerades as Akt: you don't have to look like Akt, to act like it.

Authors:  Uyanga Chuluunbaatar; Ian Mohr
Journal:  Cell Cycle       Date:  2011-07-01       Impact factor: 4.534

2.  Sepsis-induced alterations in protein-protein interactions within mTOR complex 1 and the modulating effect of leucine on muscle protein synthesis.

Authors:  Abid A Kazi; Anne M Pruznak; Robert A Frost; Charles H Lang
Journal:  Shock       Date:  2011-02       Impact factor: 3.454

3.  Hypoxia upregulates Rab11-family interacting protein 4 through HIF-1α to promote the metastasis of hepatocellular carcinoma.

Authors:  F Hu; X Deng; X Yang; H Jin; D Gu; X Lv; C Wang; Y Zhang; X Huo; Q Shen; Q Luo; F Zhao; T Ge; F Zhao; W Chu; H Shu; M Yao; J Fan; W Qin
Journal:  Oncogene       Date:  2015-03-09       Impact factor: 9.867

4.  Epidermal growth factor-induced vacuolar (H+)-atpase assembly: a role in signaling via mTORC1 activation.

Authors:  Yanqing Xu; Amanda Parmar; Emmanuelle Roux; Alejandro Balbis; Victor Dumas; Stephanie Chevalier; Barry I Posner
Journal:  J Biol Chem       Date:  2012-06-11       Impact factor: 5.157

5.  Limited therapeutic effect of N-acetylcysteine on hepatic insulin resistance in an experimental model of alcohol-induced steatohepatitis.

Authors:  Mashiko Setshedi; Lisa Longato; Dennis R Petersen; Martin Ronis; William C Chen; Jack R Wands; Suzanne M de la Monte
Journal:  Alcohol Clin Exp Res       Date:  2011-07-25       Impact factor: 3.455

6.  Intestinal cell kinase (ICK) promotes activation of mTOR complex 1 (mTORC1) through phosphorylation of Raptor Thr-908.

Authors:  Di Wu; Jessica R Chapman; Lifu Wang; Thurl E Harris; Jeffrey Shabanowitz; Donald F Hunt; Zheng Fu
Journal:  J Biol Chem       Date:  2012-02-22       Impact factor: 5.157

7.  PRAS40 deregulates apoptosis in Ewing sarcoma family tumors by enhancing the insulin receptor/Akt and mTOR signaling pathways.

Authors:  Dan Lv; Jinye Liu; Lianying Guo; Dawei Wu; Ken Matsumoto; Lin Huang
Journal:  Am J Cancer Res       Date:  2016-01-15       Impact factor: 6.166

8.  Phosphorylation of interleukin (IL)-24 is required for mediating its anti-cancer activity.

Authors:  Janani Panneerselvam; Manish Shanker; Jiankang Jin; Cynthia D Branch; Ranganayaki Muralidharan; Yan D Zhao; Sunil Chada; Anupama Munshi; Rajagopal Ramesh
Journal:  Oncotarget       Date:  2015-06-30

9.  Quantitative phosphoproteomics reveals novel phosphorylation events in insulin signaling regulated by protein phosphatase 1 regulatory subunit 12A.

Authors:  Xiangmin Zhang; Danjun Ma; Michael Caruso; Monique Lewis; Yue Qi; Zhengping Yi
Journal:  J Proteomics       Date:  2014-06-25       Impact factor: 4.044

10.  Akt phosphorylation on Thr308 but not on Ser473 correlates with Akt protein kinase activity in human non-small cell lung cancer.

Authors:  E E Vincent; D J E Elder; E C Thomas; L Phillips; C Morgan; J Pawade; M Sohail; M T May; M R Hetzel; J M Tavaré
Journal:  Br J Cancer       Date:  2011-04-19       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.